Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB07010 + hemagglutinin antigens
- Development stage
- Unknown
- Lead developer
- Advagene
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DCB07010 + hemagglutinin antigens is an adjuvanted influenza vaccine candidate developed by the Development Center for Biotechnology (DCB) in Taiwan. The product consists of trivalent influenza hemagglutinin (HA) antigens combined with DCB07010, a novel recombinant protein adjuvant. DCB07010 is a detoxified mutant of the *Escherichia coli* heat-labile enterotoxin (LT), specifically engineered to retain the potent immunostimulatory properties of the toxin while eliminating its diarrheagenic toxicity. The adjuvant acts by enhancing the activation of antigen-presenting cells and promoting a robust immune response to the HA antigens. This combination has been evaluated in Phase 1 clinical trials to assess its safety and immunogenicity for the prevention of seasonal influenza.
- Other names
- DCB07010-adjuvanted trivalent influenza vaccineDCB-07010-adjuvanted trivalent influenza vaccineDCB 07010-adjuvanted trivalent influenza vaccineDCB07010 adjuvanted influenza vaccineDCB-07010 adjuvanted influenza vaccineDCB 07010 adjuvanted influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on DCB07010 + hemagglutinin antigens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCB07010 + hemagglutinin antigens.